Cynata Therapeutics Limited (CYYNF)

Market Cap	49.06M +60.2%
Revenue (ttm)	1.13M -3.0%
Net Income	-5.61M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,500
Average Volume	3,264
Open	0.2200
Previous Close	0.1500
Day's Range	0.2200 - 0.2200
52-Week Range	0.0800 - 0.2200
Beta	1.04
RSI	49.19
Earnings Date	May 27, 2026

About Cynata Therapeutics

Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; CYP-006TK, a n...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 2
• Stock Exchange: OTCMKTS
• Ticker Symbol: CYYNF

Financial Performance

In fiscal year 2025, Cynata Therapeutics's revenue was 1.89 million, a decrease of -18.59% compared to the previous year's 2.32 million. Losses were -9.39 million, -3.63% less than in 2024.

Financial numbers in AUD